Tulay Kus1, Gokmen Aktas2, Mehmet Emin Kalender2, Alper Sevinc2, Seval Kul3, Ali Suner4, Esra Ulker5, Celaletdin Camci2. 1. Department of Internal Medicine, Division of Medical Oncology, Gaziantep Oncology Hospital, University of Gaziantep, TR-27310, Gaziantep, Turkey. drtulaykus83@hotmail.com. 2. Department of Internal Medicine, Division of Medical Oncology, Gaziantep Oncology Hospital, University of Gaziantep, TR-27310, Gaziantep, Turkey. 3. Department of Biostatistics, Faculty of Medicine, University of Gaziantep, TR-27310, Gaziantep, Turkey. 4. Department of Internal Medicine, Division of Medical Oncology, University of Adıyaman, TR-02030, Adıyaman, Turkey. 5. Department of Internal Medicine, University of Gaziantep, TR-27310, Gaziantep, Turkey.
Abstract
PURPOSE: The purpose of this study was to determine whether the presence of diabetes mellitus (DM) influences the incidence and severity of peripheral sensory neuropathy (PSN) in patients using taxane therapy. METHODS: A retrospective single-center analysis was conducted: Patients with PSN at baseline were excluded. The incidence of PSN was evaluated retrospectively in patient subgroups who received taxane arm and taxane-plus-platinum-agents combination arm with or without known DM at baseline. RESULTS: Three hundred seventy-four patients were enrolled in this study, 81 (21.6%) of patients had DM at baseline. The incidence of grade 1 PSN (non-DM/DM) in patients receiving taxane-based chemotherapy was 33.4/25.9% and more than grade 2 PSN (non-DM/DM) was 15/34.6%. The rate of neuropathy of non-diabetic patients was 48.8%, while the rate of diabetic patients was 52.8 and 75% in DM duration below 5 years and above 5 years group, respectively. CONCLUSIONS: This retrospective analysis indicates that taxane-based therapy in DM patients whose disease duration is above 5 years appears to affect the incidence and severity of PSN without known baseline neuropathy. The probability of PSN with taxane-based therapy was similar in DM duration below 5 years and non-DM patients.
PURPOSE: The purpose of this study was to determine whether the presence of diabetes mellitus (DM) influences the incidence and severity of peripheral sensory neuropathy (PSN) in patients using taxane therapy. METHODS: A retrospective single-center analysis was conducted: Patients with PSN at baseline were excluded. The incidence of PSN was evaluated retrospectively in patient subgroups who received taxane arm and taxane-plus-platinum-agents combination arm with or without known DM at baseline. RESULTS: Three hundred seventy-four patients were enrolled in this study, 81 (21.6%) of patients had DM at baseline. The incidence of grade 1 PSN (non-DM/DM) in patients receiving taxane-based chemotherapy was 33.4/25.9% and more than grade 2 PSN (non-DM/DM) was 15/34.6%. The rate of neuropathy of non-diabeticpatients was 48.8%, while the rate of diabeticpatients was 52.8 and 75% in DM duration below 5 years and above 5 years group, respectively. CONCLUSIONS: This retrospective analysis indicates that taxane-based therapy in DMpatients whose disease duration is above 5 years appears to affect the incidence and severity of PSN without known baseline neuropathy. The probability of PSN with taxane-based therapy was similar in DM duration below 5 years and non-DMpatients.
Authors: J M Nabholtz; K Gelmon; M Bontenbal; M Spielmann; G Catimel; P Conte; U Klaassen; M Namer; J Bonneterre; P Fumoleau; B Winograd Journal: J Clin Oncol Date: 1996-06 Impact factor: 44.544
Authors: Dawn L Hershman; Louis H Weimer; Antai Wang; Grace Kranwinkel; Lois Brafman; Deborah Fuentes; Danielle Awad; Katherine D Crew Journal: Breast Cancer Res Treat Date: 2010-12-03 Impact factor: 4.872
Authors: Christopher M Peters; Juan Miguel Jimenez-Andrade; Beth M Jonas; Molly A Sevcik; Nathan J Koewler; Joseph R Ghilardi; Gilbert Y Wong; Patrick W Mantyh Journal: Exp Neurol Date: 2006-09-26 Impact factor: 5.330
Authors: G Fountzilas; H P Kalofonos; U Dafni; C Papadimitriou; D Bafaloukos; P Papakostas; A Kalogera-Fountzila; H Gogas; G Aravantinos; L A Moulopoulos; T Economopoulos; D Pectasides; N Maniadakis; V Siafaka; E Briasoulis; C Christodoulou; D Tsavdaridis; P Makrantonakis; E Razis; P Kosmidis; D Skarlos; M A Dimopoulos Journal: Ann Oncol Date: 2004-10 Impact factor: 32.976
Authors: Dawn L Hershman; Joseph M Unger; Katherine D Crew; Cathee Till; Heather Greenlee; Lori M Minasian; Carol M Moinpour; Danika L Lew; Louis Fehrenbacher; James L Wade; Siu-Fun Wong; Michael J Fisch; N Lynn Henry; Kathy S Albain Journal: J Natl Cancer Inst Date: 2018-06-01 Impact factor: 13.506
Authors: Dawn L Hershman; Cathee Till; Jason D Wright; Danielle Awad; Scott D Ramsey; William E Barlow; Lori M Minasian; Joseph Unger Journal: J Clin Oncol Date: 2016-06-20 Impact factor: 44.544
Authors: Hannah C Timmins; David Mizrahi; Tiffany Li; Matthew C Kiernan; David Goldstein; Susanna B Park Journal: J Cancer Surviv Date: 2021-01-12 Impact factor: 4.442
Authors: U Anido-Herranz; N Fernández-Núñez; J Afonso-Afonso; L Santomé-Couto; A Medina-Colmenero; O Fernández-Calvo; M Lázaro-Quintela; S Vázquez Journal: Clin Transl Oncol Date: 2018-07-26 Impact factor: 3.405
Authors: Susan Storey; Andrea Cohee; Diane Von Ah; Eric Vachon; Noah R Zanville; Patrick O Monahan; Timothy E Stump; Victoria L Champion Journal: J Patient Cent Res Rev Date: 2020-10-23
Authors: Hannah C Timmins; Tiffany Li; David Goldstein; Terry Trinh; David Mizrahi; Michelle Harrison; Lisa G Horvath; Michael Friedlander; Matthew C Kiernan; Susanna B Park Journal: J Cancer Surviv Date: 2021-02-27 Impact factor: 4.442